Sonepcizumab which is a biospecific monoclonal antibody against S1P was shown to prevent tumor progression through S1P neutralization in xenograft and allograft tumor mouse models as well as in in vitro studies using human umbilical vein endothelial cells (HUVECs) [203], making it a promising cancer therapeutic strategy. The gene discussed is MBTPS1; the disease is cancer.